West Pharmaceutical (WST) PT Raised to $370 at BofA Securities

BofA Securities analyst Derik de Bruin raised the price target on West Pharmaceutical (NYSE: WST) to $370.00 (from $310.00) while maintaining a Buy rating.

The analyst comments "Looking ahead to 2026, the key takeaway was mgmt not pushing back on ~6% topline growth (we believe there could be further upside to that). Mgmt also addressed concerns around the CGM wind-down in 2H26 (-$40mn impact, yoy no change), noting that while replacement revenue may not be fully 1:1, they are actively backfilling with higher opportunities. Additionally, the Dublin facility to expected to continue ~$20mn, helping to offset the CGM impact. The topline should also translate into robust margins (WST would only confirm some margin expansion, but we believe this could be >100bps yoy)."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• AI/ML Innovations plans $2M private placement on the CSE
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy